The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).
Halle C. F. Moore
No relevant relationships to disclose
Joseph M. Unger
No relevant relationships to disclose
Kelly-Anne Phillips
No relevant relationships to disclose
Frances M. Boyle
No relevant relationships to disclose
Erika Hitre
No relevant relationships to disclose
David James Porter
No relevant relationships to disclose
Prudence A. Francis
Other Remuneration - AstraZeneca
Lori M. Minasian
No relevant relationships to disclose
Richard D. Gelber
Research Funding - AstraZeneca
Lori J. Goldstein
No relevant relationships to disclose
Henry Leonidas Gomez
No relevant relationships to disclose
Carlos Vallejos
No relevant relationships to disclose
Ann H. Partridge
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
William E. Barlow
No relevant relationships to disclose
Carol J. Fabian
No relevant relationships to disclose
Frank L. Meyskens
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - AstraZeneca
Kathy S. Albain
No relevant relationships to disclose